ERBB2 and breast carcinoma: T-DM1 and T-DXd have shown activity in HER2-mutant lung cancer [51,52], and the ongoing DPT01 basket study (NCT04639219) is assessing the activity of T-DXd in patients with solid tumors with activating HER2 mutations, including patients with advanced breast cancer.